Ballentine Partners LLC Has $8.04 Million Stake in Eli Lilly and Company (NYSE:LLY)

Ballentine Partners LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 8.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,793 shares of the company’s stock after acquiring an additional 1,069 shares during the quarter. Ballentine Partners LLC’s holdings in Eli Lilly and Company were worth $8,040,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the third quarter valued at $27,000. Retirement Group LLC raised its holdings in Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $33,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $35,000. Finally, Optiver Holding B.V. bought a new position in Eli Lilly and Company in the third quarter valued at approximately $36,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 1.6 %

LLY traded up $12.03 during midday trading on Wednesday, reaching $775.99. The company’s stock had a trading volume of 2,892,642 shares, compared to its average volume of 3,216,040. The stock’s 50-day moving average is $742.32 and its 200-day moving average is $642.33. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $737.31 billion, a price-to-earnings ratio of 134.10, a PEG ratio of 1.67 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $351.27 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.09 EPS. As a group, research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the transaction, the insider now owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 195,055 shares of company stock worth $125,254,657 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $700.00.

View Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.